Zenas BioPharma refreshes at-the-market program with new $200 million prospectus supplement
The company replaced its prior ATM arrangement after selling about $153.2 million of the original $200 million authorization, filing a new supplement on November 6, 2026.
Zenas BioPharma, Inc. disclosed in an 8-K dated November 6, 2026 that it has updated its at-the-market equity offering program. The company had entered into a Sales Agreement with Jefferies LLC on October 8, 2025, covering an at-the-market offering program under which Zenas may sell shares of its common stock at its discretion through Jefferies as sales agent.1
That offering was conducted under a Form S-3ASR registration statement filed with the SEC on October 8, 2025, paired with a sales agreement prospectus supplement covering up to $200,000,000 in aggregate offering price of shares.1 As of the November 6, 2026 filing date, Zenas had sold roughly $153.2 million of shares under that prior prospectus supplement, leaving about $46.8 million unsold.1
On November 6, 2026, the company filed an additional prospectus supplement authorizing the offer and sale of up to another $200,000,000 in common stock under the same Sales Agreement.1 As a result, the prior prospectus supplement's offering has been terminated, and no further shares will be sold under it.1 The new shares will instead be offered under the original registration statement, which became automatically effective upon filing.1
Ropes & Gray LLP, counsel to the company, issued a legal opinion related to the new prospectus supplement shares, attached as Exhibit 5.1 to the filing.1 The 8-K specifies that it does not itself constitute an offer to sell or a solicitation to buy the new shares in any jurisdiction where such activity would be unlawful without proper registration.1 The filing was signed by Joseph L. Farmer, President and Chief Operating Officer, on November 6, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.